SNDX-5613

SKU: orb1309080

Description

Revumenib (SNDX-5613) is a potent and selective oral inhibitor that disrupts the menin-KMT2A protein interaction with sub-nanomolar affinity. It is utilized in research on acute leukemias harboring MLL rearrangements, showing activity in both cellular assays and in vivo animal models.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 2169919-21-3
• MW: 630.82
• Purity: 99.12%
• Formula: C₃₂H₄₇FN₆O₄S
• SMILES: CCN(C(C)C)C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(C1)CCN(C[C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)CC2
• Target: Histone Methyltransferase,Epigenetic Reader Domain
• Solubility: 10% DMSO+40% PEG300+5% Tween-80+45% Saline:4 mg/mL (6.34 mM);DMSO:52 mg/mL (82.43 mM)

Bioactivity

• Target IC50:
  Menin-MLL:10-20 nM
• In Vivo:
  SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) .
• In Vitro:
  METHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured. RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

acute, ALL, AML, myeloid, inhibit, Inhibitor, lymphoblastic, MLL, Leukemia, Menin, Menin-MLL, HistoneMethyltransferase, Histone Methyltransferase, Epigenetic Reader Domain, EpigeneticReaderDomain, SNDX 5613, SNDX5613, SNDX-5613

Compound Identifiers

PubChem CID

132212657